Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

This study found that the computer-controlled RV-01 scalp cooling device helped prevent significant hair loss in metastatic breast cancer patients treated with eribulin, with none of the 16 patients requiring a wig and experiencing minimal discomfort.

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

The authors describe drug repurposing as a promising strategy for finding new uses for existing drugs, noting it is efficient, cost-effective, and poses lower risks than traditional drug discovery processes, potentially aiding in the treatment of rare and difficult-to-treat diseases.

This review discusses the impact of oncological therapy on hair loss, highlighting that while most alopecia is reversible, it can be permanent depending on treatment type and factors.

This review provides a comprehensive overview of multidisciplinary dermo-aesthetic interventions for breast cancer patients, aiming to establish safe protocols involving various specialists to improve quality of life, although consultation with an oncologist before treatment is advised.

This review discusses the potential of 3D cell cultures, particularly Patient-Derived Organoids, in advancing research on liposarcoma by addressing limitations of 2D cultures and animal models but reports no new experimental findings.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.

This article reviews strategies for managing the side effects of cytotoxic chemotherapy in primary healthcare settings and reports no new clinical findings.

This study used molecular docking simulations to identify approved drugs, including Bedaquiline and Telmisartan, with potential to treat Onchocerca volvulus infections by inhibiting key protein targets, suggesting these drugs could be repurposed for onchocerciasis treatment with further validation.

This study introduces Kalya Research, an AI-driven tool designed to identify and categorize literature on complementary and alternative medicines, showing its effectiveness compared to Medline in finding relevant alopecia research within the context of breast cancer patients.

This review outlines a systematic approach for dermatologists to accurately diagnose hair loss disorders, emphasizing the importance of differentiating between scarring and non-scarring alopecia to guide appropriate treatment decisions.

This review discusses drugs and mechanisms possibly responsible for chemical- and drug-induced hair loss but presents no new research findings.

This study concluded that the receptor-like kinase ERULUS, regulated by auxin, is crucial for modulating cell wall composition and pectin dynamics during root hair growth in Arabidopsis.

In this study, researchers explored ubiquitination patterns in healthy human skin and CYLD cutaneous syndrome tumors, identifying extensive ubiquitin sites and differential protein ubiquitination linked to tumor pathology, highlighting the role of ubiquitination in tissue architecture and disease mechanisms.

This article discusses the crucial role of root hairs in water and nutrient uptake from soil and reports no new findings.

This workshop reviewed various roles of endoplasmic reticulum chaperones, including calreticulin, in cellular signaling, disease states, and potential markers, but reports no new experimental findings.

This study reports on an ongoing Phase I/IIa clinical trial of ex vivo gene therapy for treating severe Recessive Dystrophic Epidermolysis Bullosa, involving six adult participants with COL7A1 mutations resulting in deficient type VII collagen production.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

In this study, KC-AD-MSCs were found to increase COL7 deposition and anchoring fibril formation at the dermal-epidermal junction in a RDEB mouse model, suggesting potential for improving skin integrity in recessive dystrophic epidermolysis bullosa patients.

In this study, EREG promoted hair growth by activating specific receptors in cell and animal models, indicating it may be a potential treatment for hair loss.

This study by Bansaccal et al. found that skin with higher levels of type I collagen density and elasticity in the dermis can inhibit basal cell carcinoma development and spread by acting as a natural barrier against cell reprogramming in mice.

This report details a case of dystrophic epidermolysis bullosa in a 37-year-old male with a recessive mutation in the CLO7A1 gene, affecting type VII collagen.

This study identified that dominant mutations in the KLHL24 gene cause epidermolysis bullosa through dysregulated autoubiquitination, leading to excessive degradation of keratin 14.

EF and PXE not closely related.

This review outlines the genetic basis of GABEB, highlighting reduced type XVII collagen as a distinguishing marker from Herlitz JEB, and discusses potential therapeutic avenues without presenting new results.

This article reviews the multifunctional roles of calreticulin outside the ER and highlights its impact on wound healing in animal models, but reports no new clinical results.